Melanoma-associated antigen-A3 vaccination in the treatment of non-small-cell lung cancer

Adam, Valerie; Wauters, Isabelle; Vansteenkiste, Johan

doi:10.1517/14712598.2014.880421

Cited by 7 publications

(6 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, the addition of an antigen‐specific treatment in the form of a vaccine may increase the rate of responders to immune checkpoint targeted therapy. It has been shown that vaccines against MAGE‐A3 as well as NY‐ESO‐1 can successfully induce the development of specific T‐cell responses . Because of their high tumor‐specificity and their immunogenicity, these antigens may represent a good target for specific immunotherapy of ACC.…”

Section: Discussionmentioning

confidence: 99%

Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neck

Veit¹,

Heine²,

Thierauf³

et al. 2016

Head Neck

View full text Add to dashboard Cite

Background Adenoid cystic carcinoma of the head and neck (ACC) is a rare but highly malignant tumor. Cancer testis antigens (CTA) represent an immunogenic family of cancer-specific proteins and thus represent an attractive target for immunotherapy. Methods Eighty-four cases of ACC were identified, the CTAs pan-MAGE (M3H67) and NY-ESO-1 (E978) were detected immunohistochemically and correlated with clinical data. Results Expression of NY-ESO-1 was found in 48/84 (57.1%) and of pan-MAGE in 28/84 (31.2%). Median OS in NY-ESO-1 positive vs. negative patients was 130.8 and 282.0 months (p=0.223), respectively. OS in pan-MAGE positive vs. negative patients was 105.3 and 190.5 months, respectively (p=0.096). Patients expressing both, NY-ESO-1 and pan-MAGE simultaneously had significantly reduced OS with a median of 90.5 months compared to 282.0 months in negative patients (p=0.047). Conclusions A significant fraction of ACC patients show expression of the cancer testis antigens NY-ESO-1 and/or Pan-MAGE with promising immunotherapeutic implications.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neck

Veit¹,

Heine²,

Thierauf³

et al. 2016

Head Neck

View full text Add to dashboard Cite

show abstract

“…The approved Sipuleucel-T for the treatment of metastatic prostate cancer is generated by challenging ex vivo DCs with recombinant prostatic acid phosphatase (PAP) antigen fused with GM-CSF, which enhances antigen presentation and activation of T cells against tumor cells [ 93 ]. The cancer vaccine based on direct administration of melanoma-associated antigen-A3 (MAGE-A3), a member of tumor-specific antigens expressed by various cancerous cells, is giving promising results in the treatment of resected stage IB/II non-small cell lung cancer [ 94 ]. Interestingly, emerging clinical studies on the combination of cancer vaccines (DC- or peptide-based) with ICIs (anti-CTLA4 or anti-PD-1) have shown encouraging results in melanoma patients [ 95 , 96 ].…”

Section: Cancer Immunotherapymentioning

confidence: 99%

Lipid Metabolism and Cancer Immunotherapy: Immunosuppressive Myeloid Cells at the Crossroad

Bleve

Durante

Sica

et al. 2020

IJMS

View full text Add to dashboard Cite

Cancer progression generates a chronic inflammatory state that dramatically influences hematopoiesis, originating different subsets of immune cells that can exert pro- or anti-tumor roles. Commitment towards one of these opposing phenotypes is driven by inflammatory and metabolic stimuli derived from the tumor-microenvironment (TME). Current immunotherapy protocols are based on the reprogramming of both specific and innate immune responses, in order to boost the intrinsic anti-tumoral activity of both compartments. Growing pre-clinical and clinical evidence highlights the key role of metabolism as a major influence on both immune and clinical responses of cancer patients. Indeed, nutrient competition (i.e., amino acids, glucose, fatty acids) between proliferating cancer cells and immune cells, together with inflammatory mediators, drastically affect the functionality of innate and adaptive immune cells, as well as their functional cross-talk. This review discusses new advances on the complex interplay between cancer-related inflammation, myeloid cell differentiation and lipid metabolism, highlighting the therapeutic potential of metabolic interventions as modulators of anticancer immune responses and catalysts of anticancer immunotherapy.

show abstract

“…The melanoma-associated antigen-A3 (MAGE-A3) is expressed on cancer cells and found in normal testis and placental cells. 46 Despite being found in normal adult tissue, its presence is not immunogenic because it does not harness human leukocyte antigen (HLA) molecules. MAGE-A3 is overexpressed in nearly 40% of stage I–II NSCLCs.…”

Section: Promoting Release Of Cancer Antigensmentioning

confidence: 99%

New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1

Villanueva

Bazhenova

2018

Ther Adv Respir Dis

View full text Add to dashboard Cite

Immunotherapy has significantly altered the treatment landscape for many cancers, including non-small cell lung cancer (NSCLC). Currently approved immuno-oncology agents for lung cancer are aimed at the reversal of immune checkpoints, programmed death protein-1 (PD-1) and programmed death ligand-1 (PD-L1). Although responses to checkpoint inhibitors are encouraging, and in some cases durable, these successes are not universal among all treated patients. In order to optimize our treatment approach utilizing immunotherapy, we must better understand the interaction between cancer and the immune system and evasion mechanisms. In this review, we will provide an overview of the immune system and cancer, and review novel therapies that promote tumor antigen release for immune system detection, activate the effector T-cell response, and reverse inhibitory antitumor signals.

show abstract

Melanoma-associated antigen-A3 vaccination in the treatment of non-small-cell lung cancer

Cited by 7 publications

References 44 publications

Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neck

Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neck

Lipid Metabolism and Cancer Immunotherapy: Immunosuppressive Myeloid Cells at the Crossroad

New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1

Contact Info

Product

Resources

About